Contact information
Research groups
Colleges
Eleni Louka
MD PGDip DPhil MRCPCH FRCPath
Clinician Scientist
- CRIS-Oxford Cancer Clinical Academic Postdoctoral Research Fellow
- Honorary Paediatric Haematology Consultant
Paediatric MDS and JMML
I am a clinical academic Paediatric Haematologist and my work focuses on a group of extremely rare myeloid disorders of childhood Paediatric myelodysplastic syndromes (MDS) and Juvenile Myelomonocytic Leukaemia ( JMML) . These conditions are among the most difficult paediatric blood cancers to treat, and the aim of my research is to identify novel therapies for these conditions to improve the prognosis for these patients and enhance our understanding of paediatric leukaemias.
I gained my DPhil (PhD) at the University of Oxford, supported by the National Institute for Health and Care Research (NIHR) Rare Diseases Fellowship and specialised as a Paediatric Haematologist at the Oxford-Thames Valley Deanery. In 2019, I was awarded an NIHR Clinical Lecturer award in Paediatric Haematology. My current role as a Clinician Scientist and an Honorary Consultant Paediatric Haematologist allows me to spend the majority of my time working on basic science research and some of my time working clinically at the Oxford Children’s Hospital, where I look after children with blood cancer.
Key publications
-
Heterogeneous disease-propagating stem cells in juvenile myelomonocytic leukemia.
Louka E. et al, (2021), J Exp Med, 218
Recent publications
-
Single-cell multi-omics identifies chronic inflammation as a driver of TP53-mutant leukemic evolution.
Rodriguez-Meira A. et al, (2023), Nat Genet, 55, 1531 - 1541
-
Neutrophilic erythrophagocytosis in a child with paroxysmal cold hamoglobinuria.
Pervaiz O. et al, (2022), EJHaem, 3, 1394 - 1395
-
In utero origin of myelofibrosis presenting in adult monozygotic twins.
Sousos N. et al, (2022), Nat Med, 28, 1207 - 1211
-
Deciphering TP53 mutant Cancer Evolution with Single-Cell Multi-Omics
Rodriguez-Meira A. et al, (2022)
-
Heterogeneous disease-propagating stem cells in juvenile myelomonocytic leukemia.
Louka E. et al, (2021), J Exp Med, 218